Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax (®) ) in individuals aged &#8805; 70 years: A randomized study of a single dose versus two different two-dose schedules

Timo Vesikari; Roland Hardt; Hans C Rümke; Giancarlo Icardi; Montero Jordi; Stephane Thomas; Christine Sadorge; Anne Fiquet

doi:10.4161/hv.23412

Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax (®) ) in individuals aged ≥ 70 years: A randomized study of a single dose versus two different two-dose schedules

Timo Vesikari, Roland Hardt, Hans C Rümke, Giancarlo Icardi, Montero Jordi, Stephane Thomas, Christine Sadorge, Anne Fiquet

Research output: Contribution to journal › Article › Scientific › peer-review

29 Citations (Scopus)

Original language	English
Pages (from-to)	858-864
Journal	HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume	9
Issue number	4
DOIs	https://doi.org/10.4161/hv.23412
Publication status	Published - 2013
Publication type	A1 Journal article-refereed

Publication forum classification

Publication forum level 1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4161/hv.23412

Cite this

Vesikari, T., Hardt, R., Rümke, H. C., Icardi, G., Jordi, M., Thomas, S., Sadorge, C., & Fiquet, A. (2013). Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax (®) ) in individuals aged ≥ 70 years: A randomized study of a single dose versus two different two-dose schedules. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 9(4), 858-864. https://doi.org/10.4161/hv.23412

@article{86f633797c604a69a9de2ffcc91ad720,

title = "Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax ({\textregistered}) ) in individuals aged ≥ 70 years: A randomized study of a single dose versus two different two-dose schedules",

author = "Timo Vesikari and Roland Hardt and R{\"u}mke, {Hans C} and Giancarlo Icardi and Montero Jordi and Stephane Thomas and Christine Sadorge and Anne Fiquet",

year = "2013",

doi = "10.4161/hv.23412",

language = "English",

volume = "9",

pages = "858--864",

journal = "HUMAN VACCINES & IMMUNOTHERAPEUTICS",

issn = "2164-5515",

publisher = "Taylor & Francis",

number = "4",

}

Vesikari, T, Hardt, R, Rümke, HC, Icardi, G, Jordi, M, Thomas, S, Sadorge, C & Fiquet, A 2013, 'Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax (®) ) in individuals aged ≥ 70 years: A randomized study of a single dose versus two different two-dose schedules', HUMAN VACCINES & IMMUNOTHERAPEUTICS, vol. 9, no. 4, pp. 858-864. https://doi.org/10.4161/hv.23412

Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax (®) ) in individuals aged ≥ 70 years: A randomized study of a single dose versus two different two-dose schedules. / Vesikari, Timo; Hardt, Roland; Rümke, Hans C et al.
In: HUMAN VACCINES & IMMUNOTHERAPEUTICS, Vol. 9, No. 4, 2013, p. 858-864.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax (®) ) in individuals aged ≥ 70 years: A randomized study of a single dose versus two different two-dose schedules

AU - Vesikari, Timo

AU - Hardt, Roland

AU - Rümke, Hans C

AU - Icardi, Giancarlo

AU - Jordi, Montero

AU - Thomas, Stephane

AU - Sadorge, Christine

AU - Fiquet, Anne

PY - 2013

Y1 - 2013

U2 - 10.4161/hv.23412

DO - 10.4161/hv.23412

M3 - Article

SN - 2164-5515

VL - 9

SP - 858

EP - 864

JO - HUMAN VACCINES & IMMUNOTHERAPEUTICS

JF - HUMAN VACCINES & IMMUNOTHERAPEUTICS